Flavonoids as GABA<sub>A</sub> receptor ligands: the whole story?

Abstract: Benzodiazepines are the most widely prescribed class of psychoactive drugs in current therapeutic use, despite the important unwanted side effects that they produce, such as sedation, myorelaxation, ataxia, amnesia, and ethanol and barbiturate potentiation and tolerance. They exert their therapeutic effects via binding to the benzodiazepine binding site of gamma-aminobutyric acid (GABA) type A receptors, and allosterically modulating the chloride flux through the ion channel complex. First isolated from plants used as tranquilizers in folkloric medicine, some natural flavonoids have been shown to possess selective affinity for the benzodiazepine binding site with a broad spectrum of central nervous system effects. Since the initial search for alternative benzodiazepine ligands amongst the flavonoids, a list of successful synthetic derivatives has been generated with enhanced activities. This review provides an update on research developments that have established the activity of natural and synthetic flavonoids on GABA type A receptors. Flavonoids are prominent drugs in the treatment of mental disorders, and can also be used as tools to study modulatory sites at GABA type A receptors and to develop GABA type A selective agents further.

Keywords: flavonoids, GABA type A receptors, benzodiazepine binding site

Flavonoids

Flavonoids may have existed in nature for almost one billion years, and over 9000 chemically unique flavonoids have been identified in plant sources. These compounds are low molecular weight substances, found in all vascular plants, and are phenylbenzopyrones (Figure 1) with an assortment of basic structures.

Flavonoids occur as aglycones, glycosides, and methylated derivatives. In plants, flavonoid aglycones occur in a variety of structural forms. For convenience, the rings are labeled A, B, and C (Figure 1). The individual carbon atoms are based on a numbering system which uses ordinary numerals for A and C, and “primed” numerals for the B ring. The different ways of closing this ring associated with the different oxidation degrees of ring A define the various classes of flavonoids. Most flavonoids occur in natural association with sugar in conjugated form and, within any one class, may be characterized as, eg, monoglycosidic or diglycosidic. The glycosidic linkage is normally located at position 3 or 7 and the carbohydrate unit can be L-rhamnose, D-glucose, glucorhamnose, galactose, or arabinose. The chemical diversity, size, three-dimensional shape, and physical and biochemical properties of flavonoids allow them to interact with targets in different subcellular locations to influence biological activity in plants, animals, and microbes.
Apart from being important dietary components, many therapeutic benefits of flavonoids are known in animal systems. Flavonoids have antioxidant, antiproliferative, antitumor, anti-inflammatory, and proapoptotic activities, and some molecular targets have been identified. The health-promoting effects of flavonoids may relate to interactions with key enzymes, signaling cascades involving cytokines and transcription factors, or antioxidant systems.

Because flavonoids can be found ubiquitously in plants, they are major constituents of a variety of fruit and vegetables, beverages, such as tea and wine, and seeds such as cocoa beans and grape seeds. Flavonoids undergo extensive
biorientation and conjugation that occur during their absorption from the gastrointestinal tract, in the liver, and finally in cells. Dietary flavonoids are substrates for phase I and phase II enzymes in the small intestine and liver. They are deglycosylated and metabolized into glucuronides, sulfates, and O-methylated derivatives.

Flavonoid absorption from the intestine occurs by several different pathways. Flavonoid aglycones can be easily absorbed into the intestinal cells because their lipophilicity facilitates their passage across the mucosal phospholipid bilayer of cells. Lactase phlorizin hydrolase has a crucial role in the absorption of flavonoids bearing β-glycoside linkages. On the other hand, flavonoid monoglycosides can be transported by the sodium glucose transporter-1 on the brush border membrane of intestinal cells. Most flavonoid glycosides entering enterocytes are deglycosylated by β-glucosidases, namely, broad-specificity cytosolic β-glucosidase. The flavonoids appear to be subjected to glucuronidation, sulfation, and methylolation in the intestinal epithelial cells before entering circulation. The flavonoid conjugates then gain access into hepatocytes where they are further methylated, glucuronidated, or sulfated. These flavonoid conjugates are excreted into the urine and also into bile fluid, thereby returning to the intestinal lumen. Subsequently, they may be reabsorbed again, mainly in the large intestine. Further metabolism occurs in the colon, where enzymes of the gut microflora induce the breakdown of flavonoids to phenolic acids which may undergo absorption and be further metabolized in the liver. The present review focuses on advances in our knowledge pertaining to the action of flavonoids on the central nervous system, more precisely their effect on gamma amino butyric acid (GABA) type A receptors.

**GABA type A receptor**

Neuropharmacology is based simply on the fundamental balance between chemical excitation and inhibition. These processes are indispensable in the networks of neurons, and all neurons have receptors for inhibitory and excitatory neurotransmitters. The GABA system is one of the mechanisms that takes care of chemical inhibition in the brain, and has been widely used for pharmacological modulation of brain function. Most brain neurons express GABA type A receptors, which are considered to be the most important for pharmacological modulation. These receptors are heteropentameric GABA-gated chloride channels belonging to the Cys-loop ligand-gated ion channel superfamily that also includes the nicotinic acetylcholine receptors, glycine receptors, and 5-HT receptors. The subunits of all these receptors share a common ancestral structure. In addition to the rapid actions of GABA via GABA type A receptors, GABA also modulates neural activity, albeit on a slower time scale, via activation of GABA type A receptors belonging to the G protein-coupled receptor superfamily. GABA type A receptor subunits are encoded by 19 different genes that have been grouped into eight subclasses based on sequence homology (α1–6, β1–3, γ1–3, δ, ε, θ, π, ρ1–3). Alternative splicing contributes to additional receptor diversity.

Knowing the number of subunits and potential combinations, the quantity of possible receptor subtypes could be enormous. However, only 11 structurally and functionally distinct receptor subtypes have been conclusively identified and are reasonably abundant in at least parts of the brain. They represent combinations of 2α and 2β subunits, together with a single γ2 or δ subunit. A further 15 receptor subtypes exist with high probability and a more limited distribution. These numbers do not account for additional heterogeneity based on different types of α or β subunits in one receptor complex, or due to alternative splicing of subunits. GABA type A receptors with different subunit compositions exhibit different pharmacology and channel gating properties, are differentially expressed during development and in the adult brain, accumulate at different neuronal cell surfaces, and are subject to differential regulation by extracellular cues.

GABA type A receptors can be allosterically modulated by benzodiazepines, barbiturates, steroids, anesthetics, anxiolytics, and many other drugs, the number of which is constantly increasing. These compounds do not interact directly with the GABA binding site, but exert their actions by binding to allosteric sites at GABA type A receptors that influence the binding properties of other binding sites present on these receptors and so modulate GABA-induced chloride ion influx (Figure 2).

Benzodiazepines are anticonvulsive, sedative-hypnotic, and anxiolytic compounds in clinical use. They produce allosteric changes that enhance the action of GABA on GABA type A receptors, increasing the GABA-induced frequency of opening of the chloride channels and the apparent affinity of the receptor for GABA. Benzodiazepines represented a major advance in psychopharmacology in the 1960s and have been some of the most widely prescribed drugs. They are sedating and, more importantly, produce physical dependence, such that significant withdrawal symptoms are observed on treatment cessation. In addition, benzodiazepines can be drugs of abuse. This inspired the development of subtype-selective agonists, which might retain the beneficial effects of an
antianxiety and anticonvulsant profile, while no longer being sedative, ataxic, or having dependence liability.\textsuperscript{30}

The location of the benzodiazepine binding site at the $\alpha$ and $\gamma$ subunit interface indicates that the pharmacology of the benzodiazepine receptor subtypes is mainly determined by the $\alpha$ and $\gamma$ isoforms forming this site, whereas $\beta$ subunits, although needed to construct a channel, do not greatly affect the sensitivity of the GABA type A receptors to benzodiazepine ligands. The traditional benzodiazepine agonists (such as diazepam) are active at GABA type A receptors containing $\alpha_1, 2, 3, 5$, $\beta$, and $\gamma_2$.\textsuperscript{31} The benzodiazepine-sensitive GABA type A receptors can be further subdivided, in that receptors containing the $\alpha_1$ subunit have a higher sensitivity to a subpopulation of benzodiazepine ligands, such as quazepam or zolpidem (an imidazopyridine).\textsuperscript{28,31,32} Furthermore, receptors containing the $\alpha_2$ or $\alpha_3$ subunit have an intermediate affinity for zolpidem, whereas those containing $\alpha_5$ have very low affinity for this drug.

Receptors containing the $\alpha_4$ or $\alpha_6$ subunits, together with $\beta$ and $\gamma_2$, do not bind the traditional benzodiazepine agonists, including zolpidem, but demonstrate high affinity for some ligands, such as flumazenil and Ro15-4513, or brezatien.\textsuperscript{28} Both the potency and efficacy for benzodiazepine ligands depend on the nature of the $\alpha$ subunit.

The benzodiazepine binding site ligands so far identified do not distinguish well between the $\alpha_2$ and $\alpha_3$ or between the $\alpha_4$ and $\alpha_6$ subunits. However, all four subunits can produce functional channels in vitro when coexpressed with other subunits, and their differential distribution in the brain suggests that they modulate different behavioral circuitry.

The functional relevance of the receptor subtypes was revealed using a combined molecular genetic and pharmacological approach.\textsuperscript{33,34} Mouse lines were generated in which each of the benzodiazepine-sensitive GABA type A receptors (containing $\alpha_1, \alpha_2, \alpha_3$, or $\alpha_5$ subunits) was rendered insensitive to diazepam by a point mutation in the benzodiazepine binding site (eg, $\alpha_1$ H101R).\textsuperscript{35} A comparison of drug-induced behavioral responses in the mutated and wild-type mice then allowed identification of diazepam effects that were missing or reduced in the mutant mice. It was demonstrated that $\alpha_1\beta_2\gamma_2$ receptors mediate the sedative, antegrade amnestic, and some anticonvulsant actions of diazepam.\textsuperscript{35,36} The anxiolytic activity of diazepam is mediated mostly by GABA
type A receptors composed of α2βγ2 subunits and also by α3 GABA type A receptors. This allowed sedation and anxiolysis to be separated in molecular terms, mediated by different pathways that were characterized by the presence of α1- and α2-GABA type A receptors, respectively. The α2βγ2 receptors are also implicated in some of the muscle relaxant activities of diazepam. Receptors containing the α3 subunit seem to mediate the antiabsence effects of clonazepam. The α5βγ2 receptors seem to influence learning and memory.

The action of benzodiazepines can be blocked by flumazenil. However, flumazenil-insensitive positive modulation of GABA type A receptors has been described in receptors lacking a γ subunit by benzodiazepines at μM concentrations. It was found that recombinant α1β1 GABA type A receptors from the rat brain were sensitive to potentiation by benzodiazepine binding site ligands, with both diazepam and flumazenil acting as positive modulators. It was also found that classical benzodiazepines produce biphasic potentiation at rat recombinant α1β2γ2 GABA type A receptors via two distinct mechanisms. This biphasic potentiation is believed to be mediated via two sites, referred to as high-affinity and low-affinity benzodiazepine binding sites. Both sites are present on receptors composed of α1β2γ2 GABA type A subunits, and low affinity potentiation can be selectively observed at receptor combinations lacking a γ subunit, such as α1β2 GABA type A receptors. Furthermore, low affinity potentiation at both receptor combinations is insensitive to flumazenil.

**Natural flavonoids as GABA type A receptor ligands**

Nature provides science and society with a virtually unlimited supply of structurally diverse and biologically active molecules. While some are directly useful in commercial applications, others are valuable for studying and understanding biological phenomena at the molecular level. Flavonoids are only a modest example.

The first report of flavonoids as central nervous system ligands was described by Roche researchers. In their study, they were looking for the presence of “diazepam-like” endogenous ligands in bovine urine, in which they isolated a few isoflavon derivatives: (S)-7,4′-dihydroxyisoflavan (equol); dl-3′,7-dihydroxyisoflavan; dl-4′-hydroxy-7-methoxyisoflavan; dl-7-hydroxy-4′-methoxyisoflavon; 7-hydroxy-4′-methoxyisoflavone (formononetin); and 4′-hydroxy-7-methoxyisoflavone; 3′,7-dihydroxyisoflavone) (Figure 3) with low affinity for the benzodiazepine binding site. Some years later, using a radioreceptor-guided purification protocol, we were able to isolate one of these isoflavon ligands (equol) from bovine rumen contents, an important natural source of “diazepam-like” compounds. These isoflavans were most probably derived from plant sources in the bovine diet.

The next valuable antecedent in this story of flavonoids active in the central nervous system was the discovery of the biflavonoid, amentoflavone (Figure 4) as a high affinity ligand for the benzodiazepine binding site. This natural compound (Karmelitter Geist) was isolated from an extract of several commercially available medicinal plants and used to treat nervous disorders.

Amentoflavone is one of the most potent flavonoids in displacing benzodiazepine binding to rat brain membranes, but is inactive in vivo. It binds, in vitro, in a mixed-type competitive and noncompetitive manner to brain receptors, with an affinity comparable with that of diazepam. Studies on subtype specificity showed that amentoflavone had little or no affinity for α4-containing or α6-containing receptors. This biflavonoid can be extracted from Ginkgo biloba but removed from herbal preparations such as EGb 761. Using a functional assay employing recombinant GABA type A receptors expressed in oocytes, amentoflavone has been shown to be a weak negative allosteric modulator of GABA action, acting independently of classical flumazenil-sensitive benzodiazepine-modulatory sites. It was also reported that amentoflavone influences a variety of G protein-coupled receptors for serotonin, dopamine, and opioids at nM concentrations, while having no effect on the binding of muscimol, a GABA type A agonist to GABA type A receptors.

Since then and contemporary with the work described above, research in our laboratories was devoted to the identification of natural ligands for the benzodiazepine binding site in plants. In particular, we were looking for benzodiazepines or benzodiazepine-like compounds, and the discovery of the properties of amentoflavone drove our investigation to similar ligands in plants known to contain flavonoids and we also extended this study to other plants traditionally used as tranquilizers.

In vivo and in vitro studies with the principal flavonoid and flavonol derivatives (Table 1) have clarified their pharmacological actions on the binding of benzodiazepines. The first monoflavonoid described as a specific ligand for the benzodiazepine binding site was chrysin (5,7-dihydroxyflavone). This compound, isolated from Passiflora caerulea L, is a selective and competitive inhibitor of [3H]flunitrazepam binding to the benzodiazepine binding site. Chrysin is almost equipotent to diazepam as an anxiolytic, but does not exhibit
It was postulated that this natural monoflavonoid is a partial agonist of the central benzodiazepine binding site. Additionally, both intraperitoneal and oral administration of chrysin in mice produced a significant hyperalgesic effect in the tail-immersion test that involved GABA type A receptors, as does flumazenil, a specific antagonist for the benzodiazepine binding site; bicuculline, a GABA type A receptor antagonist and picrotoxin, a chloride channel blocker, could antagonize the hyperalgesia of chrysin.

The dried flower heads of <i>Matricaria recutita</i> L are used in folk medicine to prepare a spasmolytic and sedative tea.

**Figure 3** Molecular structures of (A) flavans and (B) isoflavones.
The fractionation of the aqueous extract of this plant led to the detection of several fractions with significant affinity for the benzodiazepine binding site and to the isolation and identification of apigenin (5,7,4′-trihydroxyflavone). Apigenin competitively binds to the benzodiazepine binding site of the GABA type A receptor, has clear anxiolytic activity in mice when administered intraperitoneally, without showing evidence of sedation or muscle relaxant effects at doses similar to those used for classical benzodiazepines and no anticonvulsant action. However, other studies, performed in rats, found that apigenin fitted the profile of an inverse benzodiazepine agonist and was sedative and mildly proconvulsant, but not anxiolytic. Meanwhile, others reported that apigenin fitted the profile of a benzodiazepine antagonist. The discrepancies between the in vitro and in vivo results obtained for apigenin may be due to its in vivo metabolism or the use of different

Table 1 Flavone and flavonol derivatives

<table>
<thead>
<tr>
<th>Flavone</th>
<th>Substitution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flavone</td>
<td>H H H H H H H H H</td>
</tr>
<tr>
<td>Chrysin</td>
<td>OH H H H H H H H H</td>
</tr>
<tr>
<td>Apigenin</td>
<td>OH H H H H H H H H</td>
</tr>
<tr>
<td>Kaempferol</td>
<td>OH H OH H H H H H H</td>
</tr>
<tr>
<td>Cirsiliol</td>
<td>OH OCH₃ OCH₃ H H OH OH H H</td>
</tr>
<tr>
<td>Quercetin</td>
<td>OH H OH H OH H OH OH H H</td>
</tr>
<tr>
<td>Myricetin</td>
<td>OH H OH H OH H OH OH H H</td>
</tr>
<tr>
<td>Wogonin</td>
<td>OH H OH OCH₃ H H H H H H</td>
</tr>
<tr>
<td>Oroxylin A</td>
<td>OH OCH₃ OH H H H H H H H</td>
</tr>
<tr>
<td>Cinobufagin</td>
<td>OH OCH₃ OH H H H H H H H</td>
</tr>
<tr>
<td>Skrofuline-cirsinarin</td>
<td>OH OCH₃ OCH₃ H H H H H H H</td>
</tr>
<tr>
<td>5,7-dimethoxyflavone</td>
<td>OCH₃ H OCH₃ H H H H H H H</td>
</tr>
<tr>
<td>5,7-dimethoxy-6-methylflavone</td>
<td>OCH₃ CH₃ OCH₃ H H H H H H</td>
</tr>
<tr>
<td>5-hydroxy-7-methoxy-6-methylflavone</td>
<td>OH CH₃ OCH₃ H H H H H H</td>
</tr>
<tr>
<td>5-hydroxy-7-methoxy-6,8-dimethylflavone</td>
<td>OH CH₃ OCH₃ CH₃ H H H H H H</td>
</tr>
<tr>
<td>6-Methylapigenin</td>
<td>OH CH₃ OH H H H H OH H H</td>
</tr>
<tr>
<td>Luteolin</td>
<td>OH H OH H H H OH OH H H</td>
</tr>
<tr>
<td>Baicalin</td>
<td>OH OH OH H H H H H H</td>
</tr>
<tr>
<td>Baicalin</td>
<td>OH O-glucuronide OH H H H H H H</td>
</tr>
<tr>
<td>K36</td>
<td>OH OCH₃ OH OCH₃ H OH H H H</td>
</tr>
</tbody>
</table>
species, ie, rats or mice, because mice have higher baseline levels of anxiety. Thus, apigenin appears to have diverse effects at the benzodiazepine binding site and the nature of these effects is unclear. Overall, it seems that the effects of apigenin on GABA type A receptors are complex and involve both flumazenil-sensitive and flumazenil-insensitive components, and that other receptors could be involved in the behavioral effects of this drug.69,70

The flavonoids, kaempferol (3,5,7,4′-tetrahydroxyflavone) and cirsiliol (3,3′,4′-trihydroxy-6,7-dimethoxyflavone), isolated from Tilia tomentosa Moench and Salvia guaranitica, respectively, exhibited a very low affinity for the benzodiazepine binding site and were devoid of anxiolytic actions by the intraperitoneal route. However, cirsiliol produced sedation in mice as measured by the holeboard test and had thiopental-potentiating effects.61–63 Recently, a comparative study of the anxiolytic activity of flavonoids, kaempferol, quercetin, (3,5,7,3′,4′-pentahydroxyflavone), and myricetin (3,5,7,3′,4′,5′-hexahydroxyflavone) in the elevated plus-maze after oral and intraperitoneal administration in mice showed that only kaempferol and quercetin were active after oral administration.64 The anxiolytic activity of kaempferol was also partially antagonized by concomitant administration of flumazenil.65 No anxiolytic effects were observed when kaempferol and quercetin were given via the intraperitoneal route. However, cirsiliol produced sedation from mice as measured by the holeboard test and had thiopental-potentiating effects.61–63

Some natural and synthetic flavanones have been investigated for their ability to inhibit the binding of [3H] diazepam to rat brain membranes in vitro by a mixed competitive and noncompetitive mechanism.69,71 Hispidulin, the 6-methoxy derivative of apigenin, was further isolated, together with apigenin from Salvia officinalis (sage) using benzodiazepine binding site assay-guided fractionation.70 This flavone has been demonstrated to have anticonvulsant activity in a model of epilepsy in seizure-prone Mongolian gerbils and to cross the blood-brain barrier.71 Unlike apigenin, hispidulin has been shown to act as a positive allosteric modulator of α1,3,5,6β2γ2S GABA type A receptor subtypes.71

Daidzein (4′,7-dihydroxyisoflavone) and its 8-C glycoside, puerarin (7,4′-dihydroxy-8-C-glucosylisoflavone) (Figure 3), two isoflavones isolated from Puerariae radix, a Chinese traditional herb used to treat drunkenness and alcoholic addiction, were found to inhibit the binding of [3H] flunitrazepam to rat brain membranes.72

Leptospermum scoparium Forst contains the lipophilic flavonoids, 5,7-dimethoxyflavone, 5,7-dimethoxy-6-methyli flavone, 5-hydroxy-7-methoxy-6-methyli flavone, and 5-hydroxy-7-methoxy-6,8-dimethyli flavone, which interact specifically with the benzodiazepine binding site. A dry extract of the tincture prepared from this plant and containing these flavones induced sedative and anxiolytic effects in rats.73

Another apigenin derivative was further reported as a benzodiazepine binding site ligand. 6-Methylapigenin (4′,5,7-dihydroxy-6-methyli flavone), the 6-methyl derivative of apigenin, was isolated from the roots and rhizomes of Valeriana wallichii, a known sedative medicinal plant, and inhibited [3H] flunitrazepam binding at 0.5 µM in a manner suggesting it may be a positive modulator of GABA type A receptors.74 6-Methylapigenin induced anxiolytic effects in mice treated by the intraperitoneal route and was able to potentiate the sleep-enhancing properties of hesperidin (hesperetin 7-rhamnoglucoside), a flavone glycoside also isolated from V. wallichii and Valeriana officinalis.75

Epigallocatechin gallate (EGCG, (−)-cis-3,3′,4′,5′,7′-hexahydroxy-flavane-3-gallate) (Figure 5), a flavanol ester and a constituent of green tea, was demonstrated to exert dose-dependent anxiolytic, sedative-hypnotic, and amnesic activities after acute intraperitoneal administration in mice, that could be mediated, at least in part, by GABA type A receptors.76 In vitro, this flavonoid could also inhibit activation by GABA and enhance the modulatory action of diazepam on activation by GABA of recombinant human α1β2γ2L GABA type A receptors expressed in Xenopus laevis oocytes.78

Some natural and synthetic flavanones have been investigated in benzodiazepine binding studies. Examples are eriodictyol (5,7,3′,4′-tetrahydroxyflavanone), hesperetin
(5,7,3′-trihydroxy-4′-methoxyflavanone), and flavanone itself (Figure 5), among others. All of them were found to be inactive or only weakly active in vitro.73,79,80 However, it was recently reported that dihydromyricetin (3,5,7,3′,4′,5′-hexahydroxyflavanone) (Figure 5) is a positive modulator of GABA type A receptors at benzodiazepine binding sites that competitively inhibited [3H]flunitrazepam binding with moderate affinity. Dihydromyricetin is a flavonoid component of *Hovenia dulcis*, an herbal medicine listed among the premier antihangover plants in China that ameliorates alcohol-induced liver injuries and relieves hangover. This flavanone, administered intraperitoneally in rats, is highly effective in counteracting acute alcohol intoxication, alcohol exposure/withdrawal-induced GABA type A receptor plasticity and alcohol withdrawal syndrome symptoms, as well as reducing excessive alcohol consumption.81

Luteolin (5,7,3′,4′-tetrahydroxyflavone) is a flavonoid aglycon found in a wide variety of plants. It has been reported to displace [3H]flunitrazepam from the benzodiazepine binding site in vitro, with low affinity, and it has demonstrated anxiolytic-like effects administered orally in mice. Despite the need to analyze the interaction of luteolin with the benzodiazepine binding site further, these results suggested that by itself this interaction does not seem to explain the results observed in vivo fully, thus prompting renewed interest in the analysis of possible interactions with other receptors.82,83

Baicalein (5,6,7-trihydroxyflavone) and baicalin (baicalein 7-O-D-glucuronide), together with wogonin and oroxylin A, are the major bioactive components in *S. baicalensis*. Baicalin was reported to induce an anxiolytic-like effect devoid of sedation and myorelaxation in mice when administered orally, acting via the benzodiazepine binding site. It showed significant preference for α2-containing and α3-containing subtypes compared with α1-containing and α5-containing subtypes in whole-cell patch clamp studies.84 Baicalein and baicalin also showed neuroprotective and anticonvulsant effects in rats injected intraperitoneally and the anticonvulsant effect of baicalein was inhibited by flumazenil.85 Other authors reported that baicalein showed anxiolytic and sedative effects when administered via the intracerebroventricular route in mice, and that this central effect were blocked by pentylelenetrazole but not

---

**Figure 5** Molecular structures of flavanones and flavanols.
by flumazenil. Therefore, they concluded that the in vivo actions of baikaline could be mediated by GABAergic nonbenzodiazepine binding sites. Another naturally occurring flavonoid isolated from *S. baicalensis*, ie, K36 (5,7,2′-trihydroxy-6,8-dimethoxyflavone), exhibited the highest affinity for the benzodiazepine binding site, comparable with that of the synthetic anxiolytic, diazepam (Ki 6.05 nM). In electrophysiological experiments, K36 potentiated currents mediated by the recombinant rat α1β2γ2 GABA type A receptor expressed in *X. laevis* oocytes and this enhancement was demonstrated to act via the benzodiazepine binding site. Oral administration of K36 produced significant benzodiazepine binding site-mediated anxiolysis in the mouse elevated plus-maze, which was abolished upon coadministration of flumazenil. Sedation, myorelaxation, and motor incoordination were not observed. Structure-activity relationships utilizing synthetic flavonoids on the flavone backbone supported that 2′-hydroxyl-substitution is a critical moiety on flavonoids with regard to benzodiazepine binding site affinity.

Chalcones are unique in the flavonoid family in lacking a heterocyclic C ring and exhibit the basic structure with two benzene rings linked through an α, β-unsaturated carbonyl group. Isoliquiritigenin (2′,4′,4′-trihydroxychalcone) (Figure 4) is a chalcone compound found in *Glycyrrhiza uralensis* (licorice), *Allium ascalonicum*, *Sinofranchetia chinensis*, *Dalbergia odorifera*, and *Glycine max* L. This chalcone showed anxiolytic effects in the elevated plus-maze test administered intraperitoneally in mice and rats. It also significantly potentiated pentobarbital-induced sleep in a dose-dependent manner and this effect was fully inhibited by flumazenil. The binding affinity of isoliquiritigenin was 0.453 μM and it potentiated GABA-evoked currents on isolated dorsal raphe neurons. Thus, these results suggest that this natural chalcone produces hypnotic effects by positive allosteric modulation of the benzodiazepine binding site of the GABA type A receptor.

**Synthetic derivatives: importance of 6-substitutions on the flavonoid nucleus**

The results obtained with natural flavonoids encouraged us to attempt to increase their potency as benzodiazepine binding site ligands by introducing electronegative substituents into their molecules, because this feature was shown to be essential for the activity of the classical benzodiazepines.

Based on structure-activity relationship studies, incorporation of electronnegative groups into the C6 and C3′ on the flavone backbone was found to yield significant increases in the binding affinities for the benzodiazepine binding site. It was also shown that 2′-hydroxyl was also a critical moiety on flavonoids with regard to benzodiazepine binding. These have guided the generation of several synthetic flavonoids with high benzodiazepine binding affinity and in vivo activity, and further quantitative structure-activity relationship studies resulted in the development of several pharmacophore models.

The first report of an active derivative of flavone was a brominated compound, 6-bromoflavone. This derivative showed a high affinity for the benzodiazepine binding site and resulted in a competitive ligand for these receptors. Its pharmacological profile, when administered intraperitoneally in mice, was quite similar to that observed for diazepam. The data to date strongly suggest that 6-bromoflavone is a full agonist of the central benzodiazepine binding site. 6-Bromo-3′-nitroflavone exhibited a different affinity for benzodiazepine binding site subtypes containing the α1 and α2/3 receptors. The plus-maze test revealed that it is anxiolytic at intraperitoneal doses of 10–300 μg/kg in mice. In contrast, 6-chloro-3′-nitroflavone and 6-methyl-3′-bromoflavone had no anxiolytic effects, and their pharmacological profile manifested antagonistic actions at the benzodiazepine binding site. In turn, 6,3′-dibromoflavone and 6-nitro-3′-bromoflavone had anxiolytic effects when administered intraperitoneally in mice, with partial agonistic behavior (Table 2).

The most active anxiolytic flavone derivative prepared in our laboratory was 6,3′-dinitroflavone. A 1–30 μg/kg intraperitoneal injection of this compound in mice produced anxiolytic-like effects. It is at least 30 times more potent by weight than diazepam and 3000 times more potent than flavone. It also has a very favorable separation index, being the separation index the ratio between the minimal sedative dose and the maximal anxiolytic one. Its magnitude qualifies the pharmacological selectivity of the compound. Inhibition of [3H]flunitrazepam binding to recombinant GABA type A receptors in transiently transfected HEK293 indicated that 6,3′-dinitroflavone exhibited the highest affinity for GABA type A receptors composed of α1β2γ2 subunits and a 2–20-fold lower affinity for homologous receptors containing α2, α3, or α5 subunits. 6,3′-dinitroflavone did not elicit currents in the absence of GABA in *X. laevis* oocytes expressing any of the recombinant GABA type A receptors tested. However, 6,3′-dinitroflavone was slightly able to modulate GABA-elicted currents, similar to other benzodiazepine site ligands.
Table 2 Synthetic flavone derivatives

<table>
<thead>
<tr>
<th>Flavonoid derivative</th>
<th>Ki (μM)</th>
<th>GABA ratio</th>
<th>Pharmacological profile</th>
<th>In vivo</th>
<th>In vitro</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Predictedb</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-bromo</td>
<td>0.070</td>
<td>1.6–2.0</td>
<td>Full agonist</td>
<td>Full agonist</td>
<td>Positive modulator&lt;sup&gt;101&lt;/sup&gt;</td>
</tr>
<tr>
<td>6-methyl</td>
<td>0.125</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>Positive modulator (at sites independent of flumazenil-sensitive benzodiazepine binding site)&lt;sup&gt;102&lt;/sup&gt;</td>
</tr>
<tr>
<td>6-chloro</td>
<td>0.164</td>
<td>ND</td>
<td>ND</td>
<td>Antagonist&lt;sup&gt;101&lt;/sup&gt;</td>
<td>Neutralizing modulator&lt;sup&gt;101&lt;/sup&gt;</td>
</tr>
<tr>
<td>6-nitro</td>
<td>0.275</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>6-hydroxy</td>
<td>0.580</td>
<td>ND</td>
<td>ND</td>
<td>Partial agonist&lt;sup&gt;102&lt;/sup&gt;</td>
<td>Positive modulator&lt;sup&gt;102&lt;/sup&gt;</td>
</tr>
<tr>
<td>6-methoxy</td>
<td>0.860</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>6-fluoro</td>
<td>4.5&lt;sup&gt;12&lt;/sup&gt;</td>
<td>ND</td>
<td>Antagonist&lt;sup&gt;101&lt;/sup&gt;</td>
<td>Neutralizing modulator&lt;sup&gt;101&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Flavone</td>
<td>1&lt;sup&gt;11&lt;/sup&gt;</td>
<td>ND</td>
<td>Partial agonist</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>6-bromo-3'-nitro</td>
<td>0.001&lt;sup&gt;12&lt;/sup&gt;</td>
<td>1.38</td>
<td>Partial agonist</td>
<td>Partial agonist&lt;sup&gt;11&lt;/sup&gt;</td>
<td>ND</td>
</tr>
<tr>
<td>6-methyl-3'-nitro</td>
<td>0.005&lt;sup&gt;14&lt;/sup&gt;</td>
<td>0.72</td>
<td>Inverse agonist</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6-chloro-3'-nitro</td>
<td>0.008&lt;sup&gt;12&lt;/sup&gt;</td>
<td>1.16</td>
<td>Antagonist</td>
<td>Antagonist&lt;sup&gt;15&lt;/sup&gt;</td>
<td>ND</td>
</tr>
<tr>
<td>6,3'-dinitro</td>
<td>0.026&lt;sup&gt;17&lt;/sup&gt;</td>
<td>1.30</td>
<td>Partial agonist</td>
<td>Partial agonist&lt;sup&gt;16&lt;/sup&gt;</td>
<td>Low efficacy modulator&lt;sup&gt;19&lt;/sup&gt;</td>
</tr>
<tr>
<td>6-fluoro-3'-nitro</td>
<td>0.180&lt;sup&gt;13&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>3'-nitro</td>
<td>0.285&lt;sup&gt;12&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6,3'-dibromo</td>
<td>0.019&lt;sup&gt;12&lt;/sup&gt;</td>
<td>1.29</td>
<td>Partial agonist</td>
<td>Partial agonist&lt;sup&gt;16&lt;/sup&gt;</td>
<td>ND</td>
</tr>
<tr>
<td>6-methyl-3'-bromo</td>
<td>0.013&lt;sup&gt;14&lt;/sup&gt;</td>
<td>1.03</td>
<td>Antagonist</td>
<td>Antagonist&lt;sup&gt;14&lt;/sup&gt;</td>
<td>ND</td>
</tr>
<tr>
<td>6-chloro-3'-bromo</td>
<td>0.023&lt;sup&gt;13&lt;/sup&gt;</td>
<td>1.10</td>
<td>Antagonist</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6-nitro-3'-bromo</td>
<td>0.025&lt;sup&gt;13&lt;/sup&gt;</td>
<td>1.19</td>
<td>Partial agonist</td>
<td>Partial agonist&lt;sup&gt;16&lt;/sup&gt;</td>
<td>ND</td>
</tr>
<tr>
<td>6-fluoro-3'-bromo</td>
<td>0.236&lt;sup&gt;15&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>3'-bromo</td>
<td>0.413&lt;sup&gt;13&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6-hydroxy-3'-bromo</td>
<td>1&lt;sup&gt;16&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6-methoxy-3'-bromo</td>
<td>1&lt;sup&gt;16&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6-bromo-3'-chloro</td>
<td>0.017&lt;sup&gt;15&lt;/sup&gt;</td>
<td>1.23</td>
<td>Partial agonist</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6,3'-dichloro</td>
<td>0.023&lt;sup&gt;15&lt;/sup&gt;</td>
<td>1.10</td>
<td>Antagonist</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6-fluoro-3'-chloro</td>
<td>0.199&lt;sup&gt;15&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>3'-chloro</td>
<td>0.614&lt;sup&gt;12&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6,3'-dimethyl</td>
<td>0.29&lt;sup&gt;14&lt;/sup&gt;</td>
<td>1.63</td>
<td>Full agonist</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6-bromo-3'-methyl</td>
<td>0.154&lt;sup&gt;16&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6,3'-dimethyl</td>
<td>0.208&lt;sup&gt;16&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>3'-methyl</td>
<td>1&lt;sup&gt;16&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>3'-methoxy</td>
<td>2.4&lt;sup&gt;15&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>3'-fluoro</td>
<td>3.55&lt;sup&gt;15&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6-bromo-3'-fluoro</td>
<td>0.042&lt;sup&gt;15&lt;/sup&gt;</td>
<td>0.97</td>
<td>Antagonist-inverse agonist</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6-bromo-3'-methoxy</td>
<td>0.609&lt;sup&gt;15&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6-chloro-3'-fluoro</td>
<td>0.117&lt;sup&gt;15&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6-chloro-3'-methoxy</td>
<td>0.848&lt;sup&gt;15&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6,3'-difluoro</td>
<td>0.920&lt;sup&gt;15&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6-fluoro-3'-methoxy</td>
<td>2.5&lt;sup&gt;15&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>3-bromo</td>
<td>&gt;75&lt;sup&gt;91&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6,3'-dibromo</td>
<td>&gt;75&lt;sup&gt;91&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>3-bromo-3'-nitro</td>
<td>&gt;20&lt;sup&gt;13&lt;/sup&gt;</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
</tbody>
</table>

(Continued)
Relatively extensive pharmacological studies on our synthetic flavonoids have been conducted by other authors, and the results obtained confirmed and extended our findings.\textsuperscript{100,101} Recently, flavone analogs, each varying only in the 6-position substituent, were compared. Whole-cell patch-clamp and animal behavior experiments demonstrated 6-bromoflavone to be a positive modulator at GABA type A receptors, acting via a flumazenil-sensitive high-affinity benzodiazepine binding site. In contrast, 6-fluoroflavone and 6-chloroflavone were found to be neutralizing modulators. In patch-clamp experiments, 6-hydroxyflavone displayed a significant preference for α2-containing and α3-containing subtypes, which were thought to mediate the anxiolytic effect, compared with α1- and α5-containing subtypes expressed in HEK 293T cells. In mice, 6-hydroxyflavone exhibited anxiolytic-like effects unaccompanied by the sedative, cognitive impairment, myorelaxant, motor incoordination, and anticonvulsant effects commonly associated with classical benzodiazepines.\textsuperscript{102} In addition, in vitro electrophysiological and in vivo animal experiments showed that 2′-hydroxyflavone was an antagonist, different in efficacy from its structural analog, 6,2′-dihydroxyflavone, a negative modulator of GABA type A receptors. The fact that flavone derivatives differing only at position 6 showed drastically different pharmacological properties clearly points to 6-substitution being an important determinant of efficacy. All the results suggest that a large width of the first atom on the 6-substituent favors a high binding affinity of the 6-substituted flavone, whereas a large overall volume of the 6-substituent favors positive modulator activity, which could be modified by, eg, 2′-hydroxyl substitution.\textsuperscript{101}

6-Methyflavone was found to be a positive allosteric modulator at α1β2γ2L and α1β2 GABA type A receptors, with no significant difference between the enhancement seen at either receptor subtype, at ionotropic GABA type A receptors expressed in \textit{X. laevis} oocytes and at sites independent of the flumazenil-sensitive benzodiazepine binding site.\textsuperscript{103} Subsequently, 6-methyl flavanone (Figure 5) was also found to be a flumazenil-insensitive positive modulator of recombinant GABA type A receptors that, unlike 6-methyflavone, was subtype-selective, being a more efficacious positive modulator at α2β2γ2L receptors that at α1β2γ2L and α1β2 receptors.\textsuperscript{104} 6-Methyl flavanone differs from 6-methyflavone in having a single rather than a double bond at C2–C3; hence, this bond is crucial to the observed subtype-selective efficacy of 6-methyflavonane. Two new 6-methyflavone derivatives were recently reported, ie, 2′-methoxy-6-methyl flavone\textsuperscript{105} and 3-hydroxy-2′-methoxy-6-methyl flavone.\textsuperscript{106} 2′-Methoxy-6-methyl flavone potentiated GABA at α2β1γ2L and all α1-containing GABA type A receptor subtypes. However, it directly activated α2β2/3γ2L GABA type A receptors without potentiating GABA. This activation was attenuated by bicuculline and gabazine, but not flumazenil, indicating a novel site. In mice, when administered intraperitoneally, it displayed anxiolytic-like effects, and at higher doses induced sedation. Like in the in vitro data, the anxiolytic effects of 2′-methoxy-6-methyl flavone were not blocked by flumazenil, a benzodiazepine antagonist, but were attenuated by pentylenetrazole, a GABA type A channel blocker. These data imply that the anxiolytic effects are mediated via the GABAergic system, but not through the classical benzodiazepine binding site, despite 2′-methoxy-6-methyl flavone and commonly associated with classical benzodiazepines.\textsuperscript{102} relaxant, motor incoordination, and anticonvulsant effects unaccompanied by the sedative, cognitive impairment, myorelaxant, motor incoordination, and anticonvulsant effects. The pharmacological profile of ligands interacting in vitro with the benzodiazepine binding site can be predicted through the GABA ratios obtained in binding assays. These values are the ratio of Ki values of a competitive benzodiazepine binding site ligand measured in the presence or absence of GABA: ratios \( > 1 \) indicate compounds with agonistic profiles, ratios \( < 1 \) point to compounds with inverse agonistic profiles and ratios of about 1 indicate antagonistic profiles.\textsuperscript{108,111}

**Table 2 (Continued)**

<table>
<thead>
<tr>
<th>Flavonoid derivative</th>
<th>Ki (µM)</th>
<th>GABA ratio$^{a}$</th>
<th>Pharmacological profile Predicted$^{b}$</th>
<th>In vivo</th>
<th>In vitro</th>
</tr>
</thead>
<tbody>
<tr>
<td>2′-hydroxy</td>
<td>0.31$^{101}$</td>
<td>ND</td>
<td>ND</td>
<td>Antagonist$^{101}$</td>
<td>Neutralizing modulator$^{101}$</td>
</tr>
<tr>
<td>6.2′-dihydroxy</td>
<td>0.04$^{17}$</td>
<td>ND</td>
<td>ND</td>
<td>Partial inverse agonist$^{17}$</td>
<td>Negative modulator$^{17}$</td>
</tr>
<tr>
<td>2′-methoxy-6-methyl</td>
<td>&gt; 100$^{105}$</td>
<td>ND</td>
<td>ND</td>
<td>Partial agonist$^{105}$</td>
<td>Positive modulator (α1 and α2β1/2L subtypes)</td>
</tr>
<tr>
<td>3-hydroxy-2′-methoxy-6-methyl</td>
<td>&gt; 300$^{106}$</td>
<td>ND</td>
<td>ND</td>
<td>Partial agonist$^{106}$</td>
<td>Allosteric activator (α2β2/3 and α2β2/3γ2L containing subtypes)</td>
</tr>
</tbody>
</table>

Notes: $^{a}$Ki, ± standard error of the mean values are means of 3–5 independent determinations and estimate the inhibition of 3-H-flunitrazepam binding to rat cerebral cortical synaptosomal membranes. The standard error of the mean varies between 6% and 13% of the absolute values listed. $^{b}$The pharmacological profile of ligands interacting in vitro with the benzodiazepine binding site can be predicted through the GABA ratios obtained in binding assays. These values are the ratio of Ki values of a competitive benzodiazepine binding site ligand measured in the presence or absence of GABA: ratios > 1 indicate compounds with agonistic profiles, ratios < 1 point to compounds with inverse agonistic profiles and ratios of about 1 indicate antagonistic profiles.\textsuperscript{108,111}

Abbreviations: GABA, gamma aminobutyric acid; ND, not determined.

6-Methyflavone was found to be a positive allosteric modulator at α1β2γ2L and α1β2 GABA type A receptors, with no significant difference between the enhancement seen at either receptor subtype, at ionotropic GABA type A receptors expressed in \textit{X. laevis} oocytes and at sites independent of the flumazenil-sensitive benzodiazepine binding site.\textsuperscript{103} Subsequently, 6-methyl flavanone (Figure 5) was also found to be a flumazenil-insensitive positive modulator of recombinant GABA type A receptors that, unlike 6-methylflavone, was subtype-selective, being a more efficacious positive modulator at α2β2γ2L receptors that at α1β2γ2L and α1β2 receptors.\textsuperscript{104} 6-Methyl flavanone differs from 6-methyflavone in having a single rather than a double bond at C2–C3; hence, this bond is crucial to the observed subtype-selective efficacy of 6-methyflavanone. Two new 6-methyflavone derivatives were recently reported, ie, 2′-methoxy-6-methyl flavone\textsuperscript{105} and 3-hydroxy-2′-methoxy-6-methyl flavone.\textsuperscript{106} 2′-Methoxy-6-methyl flavone potentiated GABA at α2β1γ2L and all α1-containing GABA type A receptor subtypes. However, it directly activated α2β2/3γ2L GABA type A receptors without potentiating GABA. This activation was attenuated by bicuculline and gabazine, but not flumazenil, indicating a novel site. In mice, when administered intraperitoneally, it displayed anxiolytic-like effects, and at higher doses induced sedation. Like in the in vitro data, the anxiolytic effects of 2′-methoxy-6-methyl flavone were not blocked by flumazenil, a benzodiazepine antagonist, but were attenuated by pentylenetrazole, a GABA type A channel blocker. These data imply that the anxiolytic effects are mediated via the GABAergic system, but not through the classical benzodiazepine binding site, despite 2′-methoxy-6-methyl flavone...
weakly displacing flunitrazepam binding. These data would indicate that 2′-methoxy-6-methylflavone could bind to a novel as yet unidentified site on α2β2/3γ2L GABA type A receptors. 2′-Methoxy-6-methylflavone could serve as a tool to study the complex nature of the activation and modulation of GABA type A receptor subtypes. In addition, the synthetic flavonoid, 3-hydroxy-2′-methoxy-6-methylflavone was reported to be an anxiolytic without sedative and myorelaxant effects when administered intraperitoneally in mice, acting through positive allosteric modulation of the α2β2/3γ2L and direct activation of α4β2/3δ GABA type A receptor subtypes (Table 2).

Using 6-methylflavanone and EGCG as lead compounds, structure-activity studies led to the discovery of Fa131 (2S,3R-3-acetoxy-4′-methoxyflavan) (Figure 5) as the most efficacious compound in a series of flavonol esters with positive modulatory activity of GABA type A receptors. Interestingly, similar to barbiturates, Fa131 also acts as a weak partial agonist α1β2γ2L receptor and at higher doses exerts a negative modulatory effect. Fa131 is the first positive modulator to distinguish between the α2-subunit and α3-subunit containing GABA type A receptors, highlighting the potential of targeting flumazenil-insensitive allosteric sites in the search for new anxioselective drugs. In mice, when administered intraperitoneally, it induced an anxiolytic-like action with no sedative or myorelaxant effects, and only weak barbiturate-potentiating effects on the loss of the righting reflex test. Recently there has been a report of a new flavan, Fa173 (2S,3S-3-acetoxy-3′,4′-dimethoxyflavan) (Figure 5), which neutralizes the potentiating actions of Fa131, etomidate, and loreclezole at α1β2 and α1β2γ2L GABA type A receptors expressed in X. laevis oocytes. Furthermore potentiation of high, but not low, concentrations of diazepam can be blocked by Fa173.

A series of isoflavone derivatives was recently synthesized, and their modulatory effect was evaluated on the α1β2γ2L GABA type A receptors expressed in X. laevis oocytes. This set of isoflavones acted as positive modulators of GABA type A receptors and it was demonstrated that substitution of the A, B, and C rings plays an important role in determining GABA type A modulation activity. Flumazenil-insensitive modulation by the isoflavones suggested that these compounds might not bind to the benzodiazepine binding site.

Since the first discovery of a flavonoid as a benzodiazepine binding site ligand almost 30 years ago, an extensive collection of natural and synthetic flavonoids has been reported providing potential leads for new GABA type A receptor agents and they have already become drugs with beneficial effects in the central nervous system. The in vivo and in vitro actions of some flavonoids are more complex than a single action at the benzodiazepine binding site, and some evidence of a flavonoid site in GABA type A receptors is emerging. More studies are required in order to determine the precise site of action of these bioactive molecules on GABA type A receptors and to understand fully their mechanisms of action as modulators of brain function. Also, further investigations of type specificity of flavonoids might lead to identification of flavonoids with selective pharmacological activity, thus providing a clinically interesting lead structure. Further, the concentrations of dietary flavonoids encountered in vivo are high enough to have pharmacological activity at receptors, and the evidence also supports localization of flavonoids within the brain.

In summary, flavonoids are prominent drugs in the treatment of mental disorders, and can also be used as tools to study modulatory sites at GABA type A receptors and to develop GABA subtype-selective agents further.

Acknowledgments
We are grateful to the International Foundation for Science, Stockholm, Sweden, the National Research Council of Argentina, the University of Buenos Aires, and the Ministry of Health and the National Agency for Promotion of Science and Technology, Argentina, for financial support.

Disclosure
The authors report no conflicts of interest in this work.

References


15. Wolffram S, Block M, Ader P. Quercetin-3-glucoside is transported by the glucose carrier SGLT1 across the brush border membrane of rat small intestine. *J Nutr*. 2002;132:630–635.


94. Viola H, Marder M, Nuñez J, et al. 6-Methyl-3′-bromoflavone, a high-affinity ligand for the benzodiazepine binding site of the GABA_A receptor with some anxiolytic properties. Biochem Biophys Res Commun. 1999;262:643–646.